Evidence map›Paper›PMID 38729306›Full record

ArticleAntiviral research2024

SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2.

Kabita Pandey, Arpan Acharya, Dhananjaya Pal, Prashant Jain, Kamal Singh, Donald L Durden, Tatiana G Kutateladze, Aniruddha J Deshpande, Siddappa N Byrareddy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Antiviral Activity of Essential Oil fromMolecules (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kabita PandeyDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68131, USA.
Arpan AcharyaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68131, USA.
Dhananjaya PalMolecular Targeted Therapeutics Laboratory, Levine Cancer Institute, Charlotte, NC, 28204, USA; Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA, 92037, USA.
Prashant JainCancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92127, USA.
Kamal SinghBond Life Sciences Center, University of Missouri, Columbia, MO, USA; Department of Veterinary Pathobiology, University of Missouri, Columbia, MO, USA.
Donald L DurdenMolecular Targeted Therapeutics Laboratory, Levine Cancer Institute, Charlotte, NC, 28204, USA; Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA, 92037, USA.
Tatiana G KutateladzeDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Aniruddha J DeshpandeCancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92127, USA.
Siddappa N ByrareddyDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68131, USA. Electronic address: sid.byrareddy@unmc.edu.

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection-supplementR01DA052845 · NIDA · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI BYRAREDDY, SIDDAPPA N, MOHAN, MAHESH · 2020 to 2024
$4.0M
Limiting HIV establishment and maintenace by preserving intestinal immunityR01AI129745 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BYRAREDDY, SIDDAPPA N, PAIARDINI, MIRKO · 2017 to 2020
$3.3M
Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and CancerR01CA215651 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DURDEN, DONALD · 2018 to 2023
$2.3M
Molecular Pathogenesis of AF10-Rearranged LeukemiasR01CA262746 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Aniruddha J. Deshpande · 2022 to 2026
$2.2M
The role of JADE in HBO complexesR01HL151334 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2020 to 2023
$1.8M
Neuroimmunology of Disease Training ProgramT32NS105594 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Aditya N Bade, Howard E Gendelman · 2018 to 2026
$1.4M
Epigenetic mechanisms for regulation of p300R01GM135671 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2020 to 2023
$1.4M
NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA215651NCI NIH HHS R01 CA262746NHLBI NIH HHS R01 HL151334NIAID NIH HHS R01 AI129745NIDA NIH HHS R01 DA052845NIGMS NIH HHS R01 GM135671NINDS NIH HHS T32 NS105594
6 · The paper itself

Abstract

Despite considerable progress in developing vaccines and antivirals to combat COVID-19, the rapid mutations of the SARS-CoV-2 genome have limited the durability and efficacy of the current vaccines and therapeutic interventions. Hence, it necessitates the development of novel therapeutic approaches or repurposing existing drugs that target either viral life cycle, host factors, or both. Here, we report that SRX3177, a potent triple-activity CDK4/6-PI3K-BET inhibitor, blocks replication of the SARS-CoV-2 Omicron variant with IC

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentSARS-CoV-2Virus ReplicationAnimalsCell LineChlorocebus aethiopsCOVID-19Cyclin-Dependent Kinase 4CytidineDrug SynergismHumansHydroxylaminesLeucinePhosphoinositide-3 Kinase InhibitorsVero CellsAntiviral AgentsCyclin-Dependent Kinase 4CytidineHydroxylaminesLeucinemolnupiravirPhosphoinositide-3 Kinase InhibitorsCombinatorialEntry inhibitorMU-UNMC-2OmicronRdRp inhibitorSARS-CoV-2SRX3177Triple inhibitor

Identifiers

PMID38729306
PMCPMC11922097

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.